HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marielle Chiron Selected Research

Neoplasms (Cancer)

1/2024Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile.
10/2023Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.
10/2023The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
1/2022Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
7/2020Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials.
1/2020Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation.
1/2020Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
11/2019Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
11/2019Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
4/2016A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marielle Chiron Research Topics

Disease

13Neoplasms (Cancer)
01/2024 - 03/2012
10Multiple Myeloma
10/2023 - 09/2014
7Colorectal Neoplasms (Colorectal Cancer)
07/2020 - 06/2014
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2024 - 01/2023
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2023 - 01/2022
1Cytokine Release Syndrome
01/2024
1Lung Neoplasms (Lung Cancer)
10/2023
1Prostatic Neoplasms (Prostate Cancer)
01/2022
1Thymoma (Thymic Carcinoma)
01/2022
1Triple Negative Breast Neoplasms
07/2020
1Lymphoma (Lymphomas)
09/2014
1Non-Hodgkin Lymphoma (Lymphosarcoma)
09/2014
1Hematologic Neoplasms (Hematological Malignancy)
09/2014
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
09/2014
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
09/2014
1Leukemia
09/2014

Drug/Important Bio-Agent (IBA)

10isatuximabIBA
10/2023 - 09/2014
7afliberceptIBA
07/2020 - 06/2014
5Proteins (Proteins, Gene)FDA Link
10/2023 - 06/2014
5Monoclonal AntibodiesIBA
11/2022 - 01/2020
4AntibodiesIBA
10/2023 - 11/2019
3daratumumabIBA
10/2023 - 01/2022
3LigandsIBA
10/2023 - 01/2020
2Biomarkers (Surrogate Marker)IBA
12/2021 - 11/2019
2Dexamethasone (Maxidex)FDA LinkGeneric
12/2021 - 01/2021
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2020 - 06/2014
2Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2020 - 09/2015
1CytokinesIBA
01/2024
1AntigensIBA
01/2024
1tusamitamab ravtansineIBA
10/2023
1Membrane Glycoproteins (Membrane Glycoprotein)IBA
10/2023
1Complement Inactivating AgentsIBA
10/2023
1Immunoconjugates (Immunoconjugate)IBA
10/2023
1Cell Adhesion MoleculesIBA
10/2023
1Carcinoembryonic AntigenIBA
10/2023
1RNA (Ribonucleic Acid)IBA
10/2023
1Interleukin-3 Receptors (Interleukin 3 Receptor)IBA
01/2023
1cemiplimabIBA
01/2022
1B7-H1 AntigenIBA
01/2022
1pomalidomideIBA
12/2021
1Lenalidomide (CC 5013)FDA Link
01/2021
1iniparibIBA
07/2020
1Bispecific AntibodiesIBA
01/2020
1Complement System Proteins (Complement)IBA
01/2020
1Chimeric Antigen ReceptorsIBA
01/2020
1Neoplasm Antigens (Tumor Antigens)IBA
01/2020
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2020
1Immune Checkpoint InhibitorsIBA
01/2020
1Transforming Growth Factor beta (TGF-beta)IBA
01/2020
1Receptor for Advanced Glycation End ProductsIBA
11/2019
1Kallikreins (Kallikrein)IBA
11/2019
1Fluorouracil (Carac)FDA LinkGeneric
11/2019
1Carrier Proteins (Binding Protein)IBA
11/2019
1Irinotecan (Camptosar)FDA LinkGeneric
11/2019
1Interleukin-8 (Interleukin 8)IBA
11/2019
1Insulin-Like Growth Factor Binding Protein 1IBA
11/2019
1TenascinIBA
11/2019
1Tissue Inhibitor of MetalloproteinasesIBA
11/2019
1Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA
11/2019
1Type II Tumor Necrosis Factor ReceptorsIBA
11/2019
1Small Interfering RNA (siRNA)IBA
04/2016
1Bortezomib (Velcade)FDA Link
09/2014
1Rituximab (Mabthera)FDA Link
09/2014
1Surface Antigens (Surface Antigen)IBA
09/2014
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
09/2014
1Bevacizumab (Avastin)FDA Link
06/2014
1Tetracycline (Achromycin)FDA LinkGeneric
03/2012
1IGF Type 1 Receptor (IGF 1 Receptor)IBA
03/2012

Therapy/Procedure

7Therapeutics
01/2024 - 03/2012
2Immunotherapy
01/2021 - 01/2020
1Castration
01/2022
1Organ Transplantation
11/2019
1Injections
06/2014